The deal promises $4.8 billion, and the remaining $1 billion is contingent on the “value opportunity” of Mirati’s pipeline, according to a Bristol Myers Squibb news release.
The cancer drugmaker’s leading asset is Krazati (adagrasib), which has accelerated FDA approval for small cell lung cancer in adults with a mutation that affects about 14% of patients with the cancer.
The companies said they plan to finalize the transaction in the first half of 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
